FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016829704> ?p ?o ?g. }

• W3016829704 abstract "Appropriate antimicrobial dosing is challenging because of changes in pharmacokinetics (PK) parameters and an increase in multidrug-resistant (MDR) organisms in critically ill patients. This study aimed to evaluate the effects of an empirical therapy of high-dose versus standard-dose meropenem in sepsis and septic shock patients.We performed a prospective randomized open-label study to compare the changes of modified sequential organ failure assessment (mSOFA) score and other clinical outcomes of the high-dose meropenem (2-g infusion over 3 h every 8 h) versus the standard-dose meropenem (1-g infusion over 3 h every 8 h) in sepsis and septic shock patients. Patients' characteristics, clinical and microbiological outcomes, 14 and 28-day mortality, vasopressor- and ventilator-free days, intensive care unit (ICU) and hospital-free days, percent of the time of antibiotic concentrations above the minimum inhibitory concentration (%T>MIC), and safety were assessed.Seventy-eight patients were enrolled. Median delta mSOFA was comparable between two groups (- 1 in the high-dose group vs. - 1 in the standard-dose group; P value = 0.75). There was no difference between the two groups regarding clinical and microbiological cure, 14- and 28-day mortality, vasopressor- and ventilator-free days, and ICU- and hospital-free days. In patients admitted from the emergency department (ED) with a mSOFA score ≥ 7, the high-dose group demonstrated significantly better microbiological cure compared with the standard-dose group (75% (9/12 patients) vs. 20% (2/10 patients); P value = 0.03). Likewise, the high-dose group presented higher microbiological cure rate in patients admitted from ED who had either APACHE II score > 20 (83.3% (10/12) vs. 28.6% (2/7); P value = 0.045) or on mechanical ventilator (87.5% (7/8) vs. 23.1% (3/13); P value = 0.008) than the standard-dose group. Adverse events were comparable between the two groups.Empirical therapy with the high-dose meropenem presented comparable clinical outcomes to the standard-dose meropenem in sepsis and septic shock patients. Besides, subgroup analysis manifested superior microbiological cure rate in sepsis or septic shock patients admitted from ED.ClinicalTrials.gov, NCT03344627, registered on November 17, 2017." @default.
• W3016829704 created "2020-04-24" @default.
• W3016829704 creator A5020853246 @default.
• W3016829704 creator A5035294824 @default.
• W3016829704 creator A5038436181 @default.
• W3016829704 creator A5054339990 @default.
• W3016829704 creator A5068530899 @default.
• W3016829704 creator A5084278772 @default.
• W3016829704 creator A5065726559 @default.
• W3016829704 date "2020-04-15" @default.
• W3016829704 modified "2023-10-18" @default.
• W3016829704 title "Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial" @default.
• W3016829704 cites W1970242556 @default.
• W3016829704 cites W2054363434 @default.
• W3016829704 cites W2054938569 @default.
• W3016829704 cites W2066025123 @default.
• W3016829704 cites W2070242840 @default.
• W3016829704 cites W2093073135 @default.
• W3016829704 cites W2101416655 @default.
• W3016829704 cites W2139557348 @default.
• W3016829704 cites W2150286011 @default.
• W3016829704 cites W2167298353 @default.
• W3016829704 cites W2345473542 @default.
• W3016829704 cites W2519485429 @default.
• W3016829704 cites W2540365220 @default.
• W3016829704 cites W2576731998 @default.
• W3016829704 cites W2621049254 @default.
• W3016829704 cites W2730019495 @default.
• W3016829704 cites W2755229461 @default.
• W3016829704 cites W2767005940 @default.
• W3016829704 cites W2795915717 @default.
• W3016829704 cites W2803015713 @default.
• W3016829704 cites W2808829764 @default.
• W3016829704 cites W2884031449 @default.
• W3016829704 cites W2895932786 @default.
• W3016829704 cites W2967198136 @default.
• W3016829704 cites W3001355450 @default.
• W3016829704 cites W4239409787 @default.
• W3016829704 cites W655999930 @default.
• W3016829704 doi "https://doi.org/10.1186/s40560-020-00442-7" @default.
• W3016829704 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7158081" @default.
• W3016829704 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32318268" @default.
• W3016829704 hasPublicationYear "2020" @default.
• W3016829704 type Work @default.
• W3016829704 sameAs 3016829704 @default.
• W3016829704 citedByCount "15" @default.
• W3016829704 countsByYear W30168297042021 @default.
• W3016829704 countsByYear W30168297042022 @default.
• W3016829704 countsByYear W30168297042023 @default.
• W3016829704 crossrefType "journal-article" @default.
• W3016829704 hasAuthorship W3016829704A5020853246 @default.
• W3016829704 hasAuthorship W3016829704A5035294824 @default.
• W3016829704 hasAuthorship W3016829704A5038436181 @default.
• W3016829704 hasAuthorship W3016829704A5054339990 @default.
• W3016829704 hasAuthorship W3016829704A5065726559 @default.
• W3016829704 hasAuthorship W3016829704A5068530899 @default.
• W3016829704 hasAuthorship W3016829704A5084278772 @default.
• W3016829704 hasBestOaLocation W30168297041 @default.
• W3016829704 hasConcept C126322002 @default.
• W3016829704 hasConcept C168563851 @default.
• W3016829704 hasConcept C2776376669 @default.
• W3016829704 hasConcept C2777288759 @default.
• W3016829704 hasConcept C2777628635 @default.
• W3016829704 hasConcept C2778384902 @default.
• W3016829704 hasConcept C2779375183 @default.
• W3016829704 hasConcept C42219234 @default.
• W3016829704 hasConcept C501593827 @default.
• W3016829704 hasConcept C535046627 @default.
• W3016829704 hasConcept C71924100 @default.
• W3016829704 hasConcept C86803240 @default.
• W3016829704 hasConcept C89423630 @default.
• W3016829704 hasConcept C94665300 @default.
• W3016829704 hasConceptScore W3016829704C126322002 @default.
• W3016829704 hasConceptScore W3016829704C168563851 @default.
• W3016829704 hasConceptScore W3016829704C2776376669 @default.
• W3016829704 hasConceptScore W3016829704C2777288759 @default.
• W3016829704 hasConceptScore W3016829704C2777628635 @default.
• W3016829704 hasConceptScore W3016829704C2778384902 @default.
• W3016829704 hasConceptScore W3016829704C2779375183 @default.
• W3016829704 hasConceptScore W3016829704C42219234 @default.
• W3016829704 hasConceptScore W3016829704C501593827 @default.
• W3016829704 hasConceptScore W3016829704C535046627 @default.
• W3016829704 hasConceptScore W3016829704C71924100 @default.
• W3016829704 hasConceptScore W3016829704C86803240 @default.
• W3016829704 hasConceptScore W3016829704C89423630 @default.
• W3016829704 hasConceptScore W3016829704C94665300 @default.
• W3016829704 hasIssue "1" @default.
• W3016829704 hasLocation W30168297041 @default.
• W3016829704 hasLocation W30168297042 @default.
• W3016829704 hasLocation W30168297043 @default.
• W3016829704 hasLocation W30168297044 @default.
• W3016829704 hasOpenAccess W3016829704 @default.
• W3016829704 hasPrimaryLocation W30168297041 @default.
• W3016829704 hasRelatedWork W1975056548 @default.
• W3016829704 hasRelatedWork W2088792593 @default.
• W3016829704 hasRelatedWork W22879373 @default.
• W3016829704 hasRelatedWork W2355801133 @default.
• W3016829704 hasRelatedWork W2530793832 @default.
• W3016829704 hasRelatedWork W2755229461 @default.
• W3016829704 hasRelatedWork W2766946708 @default.

• next